Naslov
Activated Charcoal Is an Effective in vitro Removal Agent of Dabigatran and Rivaroxaban in Plasma of Patients Who Need Lupus Anticoagulant Testing

Autori
Ćelap, Ivana ; Margetić, Sandra ; Šupraha Goreta, Sandra ; Buben, Jelena

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Research and Practice in Thrombosis and Haemostasis / Cushman, Mary - Medford : John Wiley & Sons, 2019, 161-161

Skup
27th Congress of the International Society on Thrombosis and Haemostasis

Mjesto i datum
Melbourne, Australija, 06.07.2019. - 10.07.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
LA testing, DOAC, activated charcoal, interferences

Sažetak
Background : Lupus anticoagulant (LA) results could be misinterpreted, mostly due to its false positive identification, in patients treated with direct oral anticoagulants (DOACs). Aims : The aim was to investigate whether activated charcoal (AC) could be used for in vitro DOACs removal from patient plasma samples in which LA testing was ordered. Methods : The study included 30 plasma samples from patients treated with dabigatran (N=14) and rivaroxaban (N=16). Firstly, dabigatran and rivaroxaban concentrations and LA ratios was determined in native samples. Secondly, 100 mg of AC was added to 500 μL plasma sample allowing DOACs adsorption for 10 minutes. Afterwards, treated samples were centrifuged 20 minutes at 1800xg and DOACs concentrations and LA were measured in supernatant. Rivaroxaban was determined using Innovance anti- FXa assay (Siemens Healthineers, Germany) with rivaroxaban calibrator (Hyphen Biomed, France) and dabigatran was measured using Innovance DTI assay (Siemens Healthineers, Germany), funded as a part of Croatian Science Foundation research project IP- 2016- 06- 8208. LA ratio was calculated from dRVVT screen (dRVVTs) and dRVVT confirm (dRVVTc) tests using LA 1 screening and LA 2 conformation reagents (Siemens Healthineers, Germany). All measurements were performed on BCSXP coagulation analyzer (Siemens Healthineers, Germany). Statistical analysis was done using Wilcoxon and Mann- Whitney test by MedCalc Statistical Software version 18.11 (MedCalc Software, Belgium). Results : LA ratio was positive in 13/14 dabigatran and 16/16 rivaroxaban native plasma samples. LA ratio was significantly higher in both rivaroxaban and dabigatran native than in AC treated samples [1.92 vs 0.98 ; P< 0.0001 and 1.48 vs 1.04 ; P< 0.001], respectively (Table 1, Figure 1). In all AC treated plasma samples, concentrations of dabigatran and rivaroxaban were undetectable. Conclusions : AC has been found as an effective in vitro agent to overcome the effect of dabigatran and rivaroxaban on dRVVT assays confirming its potential for using before LA testing in patients treated with DOACs.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA